Andere Sprachen Hyundai Bioscience Co., Ltd.

Aktien

A048410

KR7048410005

A048410

Schlusskurs Korea S.E. Andere Börsenplätze 00:00:00 28.06.2024			% 5 Tage	% 1. Jan.
18 370 ^KRW	+0,66 %		+4,20 %	-29,62 %

20.05.	Hyundai Bioscience Co., Ltd. (KOSDAQ:A048410), CnPharm Co., Ltd. und Yeonjin Kim haben die Übernahme von 34,91% der Anteile an ADM Korea Inc. (KOSDAQ:A187660) von Mobiis Co., Ltd. (KOSDAQ:A250060).	CI
16.05.	Hyundai Bioscience Co., Ltd. meldet Ergebnis für das erste Quartal bis zum 31. März 2024	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Hyundai Bioscience Co., Ltd. announced that it expects to receive KRW 3 billion in funding	17.06.
Hyundai Bioscience Co., Ltd., CnPharm Co., Ltd. and Yeonjin Kim completed the acquisition of 34.91% stake in ADM Korea Inc. from Mobiis Co., Ltd..	20.05.
Hyundai Bioscience Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	16.05.
Hyundai Bioscience Co., Ltd. announced that it expects to receive KRW 18 billion in funding from Sangsangin Investment & Securities Co.,Ltd., Sangsangin Plus Savings Bank Co.,Ltd., Sangsangin Savings Bank	16.05.
Hyundai Bioscience's Antiviral for Dengue Fever to Enter Clinical Trials in Brazil	25.04.
Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-Based Metabolic Anticancer Drug Targeting P53 Mutation Cancer	25.04.
Hyundai Bioscience Announces Its Successful Result from A Preclinical Study of A Niclosamide-Based Oral Anticancer Drug to Treat Triple-Negative Breast Cancer	22.04.
Hyundai Bioscience to Carry Out Global Clinical Tests Aimed At Treating All Serotypes of Dengue Virus Infection	19.04.
Hyundai Bioscience Co., Ltd., CnPharm Co., Ltd. and Yeonjin Kim agreed to acquire 34.91% stake in ADM Korea Inc. from Mobiis Co., Ltd. for KRW 31 billion.	11.03.
Hyundai Bioscience Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	06.03.
Hyundai Bioscience Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14.11.
Vector Inc. completed the acquisition of additional 25.071429% stake in Vitabrid Japan Inc. from Hyundai Bioscience Co., Ltd.	31.08.23
Hyundai Bioscience Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11.08.23
Hyundai Bioscience Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	15.05.23
Hyundai Bioscience Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14.11.22
Vector Inc. agreed to acquire additional 25.071429% stake in Vitabrid Japan Inc. from Hyundai Bioscience Co., Ltd. for KRW 13.7 billion.	25.08.22
Hyundai Bioscience to request a fast track processing for its monkeypox treatment drug with the FDA	26.05.22
Hyundai Bioscience Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	16.05.22
Hyundai Bioscience Co., Ltd. Launches CP-COV03 Phase 2 Clinical Trials	12.05.22
Hyundai Bioscience Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	21.03.22

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Hyundai Bioscience Co., Ltd.

Aktien

A048410

KR7048410005

A048410

Andere Sprachen

Filter